99 related articles for article (PubMed ID: 25238284)
21. Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors.
Lin X; Chen W; Qiu Z; Guo L; Zhu W; Li W; Wang Z; Zhang W; Zhang Z; Rong Y; Zhang M; Yu L; Zhong S; Zhao R; Wu X; Wong JC; Tang G
J Med Chem; 2015 Mar; 58(6):2809-20. PubMed ID: 25734520
[TBL] [Abstract][Full Text] [Related]
22. In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.
Dasmahapatra G; Patel H; Friedberg J; Quayle SN; Jones SS; Grant S
Mol Cancer Ther; 2014 Dec; 13(12):2886-97. PubMed ID: 25239935
[TBL] [Abstract][Full Text] [Related]
23. Hydroxamic acid-based histone deacetylase (HDAC) inhibitors can mediate neuroprotection independent of HDAC inhibition.
Sleiman SF; Olson DE; Bourassa MW; Karuppagounder SS; Zhang YL; Gale J; Wagner FF; Basso M; Coppola G; Pinto JT; Holson EB; Ratan RR
J Neurosci; 2014 Oct; 34(43):14328-37. PubMed ID: 25339746
[TBL] [Abstract][Full Text] [Related]
24. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
25. Syntheses and discovery of a novel class of cinnamic hydroxamates as histone deacetylase inhibitors by multimodality molecular imaging in living subjects.
Chan CT; Qi J; Smith W; Paranol R; Mazitschek R; West N; Reeves R; Chiosis G; Schreiber SL; Bradner JE; Paulmurugan R; Gambhir SS
Cancer Res; 2014 Dec; 74(24):7475-86. PubMed ID: 25320008
[TBL] [Abstract][Full Text] [Related]
26. 5-aryl-1,3,4-thiadiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents: synthesis, bioevaluation and docking study.
Huong TT; Dung do TM; Oanh DT; Lan TT; Dung PT; Loi VD; Kim KR; Han BW; Yun J; Kang JS; Kim Y; Han SB; Nam NH
Med Chem; 2015; 11(3):296-304. PubMed ID: 25256241
[TBL] [Abstract][Full Text] [Related]
27. Synthesis, Biological Evaluation, and Computer-Aided Drug Designing of New Derivatives of Hyperactive Suberoylanilide Hydroxamic Acid Histone Deacetylase Inhibitors.
Zhang S; Huang W; Li X; Yang Z; Feng B
Chem Biol Drug Des; 2015 Oct; 86(4):795-804. PubMed ID: 25763653
[TBL] [Abstract][Full Text] [Related]
28. Histone deacetylase inhibitors derived from 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine and related heterocycles selective for the HDAC6 isoform.
Blackburn C; Barrett C; Brunson M; Chin J; England D; Garcia K; Gigstad K; Gould A; Gutierrez J; Hoar K; Rowland RS; Tsu C; Ringeling J; Wager K; Xu H
Bioorg Med Chem Lett; 2014 Dec; 24(23):5450-4. PubMed ID: 25454270
[TBL] [Abstract][Full Text] [Related]
29. SAHA-based novel HDAC inhibitor design by core hopping method.
Zang LL; Wang XJ; Li XB; Wang SQ; Xu WR; Xie XB; Cheng XC; Ma H; Wang RL
J Mol Graph Model; 2014 Nov; 54():10-8. PubMed ID: 25241128
[TBL] [Abstract][Full Text] [Related]
30. Design and optimization of novel hydroxamate-based histone deacetylase inhibitors of Bis-substituted aromatic amides bearing potent activities against tumor growth and metastasis.
Yang F; Zhang T; Wu H; Yang Y; Liu N; Chen A; Li Q; Li J; Qin L; Jiang B; Wang X; Pang X; Yi Z; Liu M; Chen Y
J Med Chem; 2014 Nov; 57(22):9357-69. PubMed ID: 25360834
[TBL] [Abstract][Full Text] [Related]
31. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
Mishima Y; Santo L; Eda H; Cirstea D; Nemani N; Yee AJ; O'Donnell E; Selig MK; Quayle SN; Arastu-Kapur S; Kirk C; Boise LH; Jones SS; Raje N
Br J Haematol; 2015 May; 169(3):423-34. PubMed ID: 25709080
[TBL] [Abstract][Full Text] [Related]
32. Aceroside VIII is a new natural selective HDAC6 inhibitor that synergistically enhances the anticancer activity of HDAC inhibitor in HT29 cells.
Ryu HW; Lee DH; Shin DH; Kim SH; Kwon SH
Planta Med; 2015 Feb; 81(3):222-7. PubMed ID: 25590368
[TBL] [Abstract][Full Text] [Related]
33. Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors.
Saijo K; Imamura J; Narita K; Oda A; Shimodaira H; Katoh T; Ishioka C
Cancer Sci; 2015 Feb; 106(2):208-15. PubMed ID: 25492515
[TBL] [Abstract][Full Text] [Related]
34. HDAC8 and STAT3 repress BMF gene activity in colon cancer cells.
Kang Y; Nian H; Rajendran P; Kim E; Dashwood WM; Pinto JT; Boardman LA; Thibodeau SN; Limburg PJ; Löhr CV; Bisson WH; Williams DE; Ho E; Dashwood RH
Cell Death Dis; 2014 Oct; 5(10):e1476. PubMed ID: 25321483
[TBL] [Abstract][Full Text] [Related]
35. Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations.
Godena VK; Brookes-Hocking N; Moller A; Shaw G; Oswald M; Sancho RM; Miller CC; Whitworth AJ; De Vos KJ
Nat Commun; 2014 Oct; 5():5245. PubMed ID: 25316291
[TBL] [Abstract][Full Text] [Related]
36. Specific inhibition of histone deacetylase 8 reduces gene expression and production of proinflammatory cytokines in vitro and in vivo.
Li S; Fossati G; Marchetti C; Modena D; Pozzi P; Reznikov LL; Moras ML; Azam T; Abbate A; Mascagni P; Dinarello CA
J Biol Chem; 2015 Jan; 290(4):2368-78. PubMed ID: 25451941
[TBL] [Abstract][Full Text] [Related]
37. Discovery of a new class of histone deacetylase inhibitors with a novel zinc binding group.
Li Y; Woster PM
Medchemcomm; 2015 Apr; 6(4):613-618. PubMed ID: 26005563
[TBL] [Abstract][Full Text] [Related]
38. Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma.
Wilmott JS; Colebatch AJ; Kakavand H; Shang P; Carlino MS; Thompson JF; Long GV; Scolyer RA; Hersey P
Mod Pathol; 2015 Jul; 28(7):884-94. PubMed ID: 25836739
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors.
Zhang X; Kong Y; Zhang J; Su M; Zhou Y; Zang Y; Li J; Chen Y; Fang Y; Zhang X; Lu W
Eur J Med Chem; 2015 May; 95():127-35. PubMed ID: 25805446
[TBL] [Abstract][Full Text] [Related]
40. HDAC Inhibitors as Novel Anti-Cancer Therapeutics.
De Souza C; Chatterji BP
Recent Pat Anticancer Drug Discov; 2015; 10(2):145-62. PubMed ID: 25782916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
